Long term results of use of azathioprine in patients with ulcerative colitis in India

World Journal of Gastroenterology

Volumn 12, Issue 45, 2006, Pages 7332-7336

  Sood, Ajit ^a   Midha, Vandana ^a   Sood, Neena ^a   Bansal, Manu ^a  

^a DAYANAND MEDICAL COLLEGE AND HOSPITAL   (India)

Author keywords

Azathioprine; Immunosuppressive; Ulcerative colitis

Indexed keywords

AZATHIOPRINE; MESALAZINE; PREDNISOLONE; SALAZOSULFAPYRIDINE;

ADOLESCENT; ADULT; AGED; ALOPECIA; BLOOD TOXICITY; CYTOPENIA; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEPATITIS; HUMAN; INDIA; LEUKOPENIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MONOTHERAPY; NAUSEA; NEUTROPENIA; PANCREATITIS; PNEUMONIA; RELAPSE; REMISSION; REVIEW; SCHOOL CHILD; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT INDICATION; ULCERATIVE COLITIS; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

EID: 33845482283     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v12.i45.7332     Document Type: Review

References (25)

1. Hong JC, Kahan BD. Immunosuppressive agents in organ transplantation: past, present, and future. Semin Nephrol 2000; 20: 108-125
2. Sartor RB. Current concepts of the etiology and pathogenesis of ulcerative colitis and Crohn's disease. Gastroenterol Clin North Am 1995; 24: 475-507
3. Bean RH. The treatment of chronic ulcerative colitis with 6-mercaptopurine. Med J Aust 1962; 49: 592-593
4. Bowen GE, Irons GV Jr, Rhodes JB, Kirsner JB. Early experiences with azathioprine in ulcerative colitis; a note of caution. JAMA 1966; 195: 460-464
5. Lamers CB, Griffioen G, van Hogezand RA, Veenendaal RA. Azathioprine: an update on clinical efficacy and safety in inflammatory bowel disease. Scand J Gastroenterol Suppl 1999; 230: 111-115
6. Jewell DP, Truelove SC. Azathioprine in ulcerative colitis: final report on controlled therapeutic trial. Br Med J 1974; 4: 627-630
7. Hawthorne AB, Logan RF, Hawkey CJ, Foster PN, Axon AT, Swarbrick ET, Scott BB, Lennard-Jones JE. Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ 1992; 305: 20-22
8. Rosenberg JL, Wall AJ, Levin B, Binder HJ, Kirsner JB. A controlled trial of azathioprine in the management of chronic ulcerative colitis. Gastroenterology 1975; 69: 96-99
9. Sood A, Midha V, Sood N, Kaushal V. Role of azathioprine in severe ulcerative colitis: one-year, placebo-controlled, randomized trial. Indian J Gastroenterol 2000; 19: 14-16
10. Kirk AP, Lennard-Jones JE. Controlled trial of azathioprine in chronic ulcerative colitis. Br Med J (Clin Res Ed) 1982; 284: 1291-1292
11. Sood A, Kaushal V, Midha V, Bhatia KL, Sood N, Malhotra V. The beneficial effect of azathioprine on maintenance of remission in severe ulcerative colitis. J Gastroenterol 2002; 37: 270-274
12. Present DH, Meltzer SJ, Krumholz MP, Wolke A, Korelitz BI. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med 1989; 111: 641-649
13. Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 2002; 50: 485-489
14. Kirschner BS. Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease. Gastroenterology 1998; 115: 813-821
15. George J, Present DH, Pou R, Bodian C, Rubin PH. The long-term outcome of ulcerative colitis treated with 6-mercaptopurine. Am J Gastroenterol 1996; 91: 1711-1714
16. Connell WR, Kamm MA, Ritchie JK, Lennard-Jones JE. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut 1993; 34: 1081-1085
17. Korelitz BI, Mirsky FJ, Fleisher MR, Warman JI, Wisch N, Gleim GW. Malignant neoplasms subsequent to treatment of inflammatory bowel disease with 6-mercaptopurine. Am J Gastroenterol 1999; 94: 3248-3253
18. Connell WR, Kamm MA, Dickson M, Balkwill AM, Ritchie JK, Lennard-Jones JE. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet 1994; 343: 1249-1252
19. Yates CR, Krynetski EY, Loennechen T, Fessing MY, Tai HL, Pui CH, Relling MV, Evans WE. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 1997; 126: 608-614
20. Kull E, Beau P. Compared azathioprine efficacy in ulcerative colitis and in Crohn's disease. Gastroenterol Clin Biol 2002; 26: 367-371
21. Campbell S, Ghosh S. Effective maintenance of inflammatory bowel disease remission by azathioprine does not require concurrent 5-aminosalicylate therapy. Eur J Gastroenterol Hepatol 2001; 13: 1297-1301
22. Sood A, Midha V, Sood N, Avasthi G. Azathioprine versus sulfasalazine in maintenance of remission in severe ulcerative colitis. Indian J Gastroenterol 2003; 22: 79-81
23. Kull E, Beau P. Compared azathioprine efficacy in ulcerative colitis and in Crohn's disease. Gastroenterol Clin Biol 2002; 26: 367-371
24. Campbell S, Ghosh S. Is neutropenia required for effective maintenance of remission during azathioprine therapy in inflammatory bowel disease? Eur J Gastroenterol Hepatol 2001; 13: 1073-1076
25. Korelitz BI, Zlatanic J, Smith MJ, Lipe RJ, Baiocco PJ, Gleim GW. Significance of WBC differential when leukopenia is induced by 6-MP for IBD. Gastroenterology 1997; 113: 1810-1811